
Opinion|Videos|June 9, 2025
Closing Thoughts About IgA Nephropathy Treatment
Panelists discuss how the management of immunoglobulin A (IgA) nephropathy is undergoing a transformative shift from symptom control to targeted disease modification, with emerging therapies offering new hope for patients while requiring thoughtful integration into clinical practice and health care systems.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
NYC Nurses Strike Enters Day 5 Amid Staffing, Safety, and Benefit Disputes
2
Respiratory Vaccination by the Numbers: COVID-19, Flu, and RSV
3
Anti-Inflammatory, Antioxidant-Rich Diets May Lower Skin Cancer Risk, Slow Biological Aging
4
Lipid Management Remains Central to Cardiovascular Risk Reduction in CKD
5





























































